Really Digital, Mr Hach!
The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
Search
The GPP Forum Report
The generalized pustular psoriasis (GPP) Forum Report summarizes and highlights the important moments form the multistakeholder GPP Forum
Access to Healthcare Strategy Innovation
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Experiences of living with cancer
We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
Diabetes dog symptoms chronic disease management
Learn about the symptoms of canine diabetes and how to manage the disease.
Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
Bees and biodiversity
At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
Social Support
People living with cancer share their perspectives on the importance of social support.
Cristian Torreblanca
Cristian Torreblanca Estrada is a Corporate Global Facilities and Engineering Senior Manager Controller in Germany – with plans for growth across the global business.
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
How fast can a cheetah run wild and free?
Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.